New Data for Stroke Drug Presented at Global Medical Conference

On a recent episode of The Price of Business, Host Kevin Price interviewed Mimi Yeh, PhD, General Manager, Lumosa Therapeutics.  Dr. Yeh outlined positive results from Lumosa’s Phase 2b clinical trial (LT3001-202) evaluating LT3001 (intravenous Odatroltide) in patients with acute ischemic stroke. Results from this study were presented during an oral presentation at the 17th World Stroke Congress (WSC 2025) held in Barcelona, Spain.

The China Phase 2b study met its primary endpoint of safety. No treatment-related symptomatic intracranial hemorrhage (sICH) was observed. Across all treatment groups, LT3001 demonstrated a consistent trend of functional improvement compared with placebo. At day 90, patients receiving LT3001 achieved a 7.3% higher rate of functional independence (mRS 0–2).  These data demonstrate consistent efficacy trends across multiple clinically meaningful subgroups, supporting LT3001’s potential to improve outcomes for stroke patients who are ineligible for current reperfusion therapies.

A second global Phase 2 study (LT3001-205; n=88), conducted in the United States, Europe, and Taiwan, also met its primary safety endpoint. No treatment-related sICH was observed. The study demonstrated efficacy trends consistent with the China trial.

These combined Phase 2 results provide critical clinical evidence supporting the continued development of LT3001 for acute ischemic stroke. Lumosa will continue its strategic collaboration with Shanghai Pharma and is actively engaging in global licensing discussions with international pharmaceutical partners.

Lumosa aims to accelerate global Phase 3 development of LT3001 and deliver innovative and effective treatment options for stroke patients worldwide.